Diagnosing Frontotemporal Dementia as a Neuropsychologist
As a neuropsychologist, you should diagnose frontotemporal dementia through a structured neuropsychological battery that includes at least one validated social cognition test (such as Ekman 60 Faces Test or Mini-SEA), executive function assessment, and evaluation across five core cognitive domains, while recognizing that standard neuropsychological tests alone have limited specificity and must be integrated with collateral history, neuroimaging findings, and biomarkers to distinguish bvFTD from psychiatric disorders. 1
Core Neuropsychological Assessment Framework
Essential Testing Battery
Your neuropsychological evaluation should systematically assess five key cognitive domains that differentiate FTD subtypes from each other and from Alzheimer's disease 2:
- Declarative memory: Patients with FTD typically perform better than those with Alzheimer's disease on memory tests, though some may show marked memory impairment in atypical presentations 3
- Working memory/visuoconstruction: Particularly impaired in progressive nonfluent aphasia and corticobasal degeneration variants 2
- Processing speed/mental flexibility: Behavioral variant FTD patients may complete tasks faster but make significantly more errors, reflecting impulsivity and disinhibition 2
- Lexical retrieval: Critical for identifying language variants 2
- Semantic memory: Profoundly impaired in semantic dementia, distinguishing it from other FTD subtypes 2
Mandatory Social Cognition Testing
You must include at least one structured social cognition test in your standard battery, as this is now a formal recommendation for bvFTD diagnosis 1. Options include:
- Ekman 60 Faces Test for emotion recognition 1
- Social Cognition and Emotional Assessment (SEA) or Mini-SEA 1
- These tests assess the patient's ability to recognize emotions, understand social cues, and demonstrate empathy—capacities that are characteristically impaired early in bvFTD 4
Executive Function Assessment
If general cognitive screening (MoCA, ACE-III) shows no abnormalities but bvFTD remains in the differential, add specific executive function tests such as the Inattention Frontal Score (IFS) or Frontal Executive Screen (FES) 1.
Critical Diagnostic Considerations
Limitations of Neuropsychological Testing Alone
A major pitfall: neuropsychological tests were found to poorly differentiate bvFTD from primary psychiatric disorders in the Late-Onset Frontal lobe study 1. Standard neuropsychological batteries have insufficient specificity (27% in mixed neuropsychiatric cases) when used in isolation 1. This means you cannot make a definitive diagnosis based solely on test performance.
Integration with Collateral Information
Your assessment must include 1:
- Detailed collateral history from informants: Essential for documenting behavioral changes that patients often lack insight into 1
- Observation of behavior during testing: Note disinhibition, apathy, loss of empathy, perseverative behaviors, and hyperorality 3
- Screening for major psychiatric symptoms: Depression, bipolar disorder, schizophrenia, and obsessive-compulsive disorder frequently mimic bvFTD 1
Diagnostic Criteria Application
For "possible" bvFTD diagnosis, you need to document three of six clinically discriminating features 3:
- Disinhibition
- Apathy/inertia
- Loss of sympathy/empathy
- Perseverative/compulsive behaviors
- Hyperorality
- Dysexecutive neuropsychological profile
Your neuropsychological findings contribute specifically to criterion #6, but the diagnosis requires convergent evidence from multiple domains 3.
Essential Multidisciplinary Integration
Neuroimaging Requirements
You cannot diagnose FTD without structural neuroimaging 1. The minimal requirement is brain MRI with T1 and FLAIR sequences including coronal cuts, reviewed by a specialized neuroradiologist for frontal and anterior temporal atrophy 1. Standard MRI has 70% sensitivity, which means 30% of cases show no clear atrophy early in disease 1.
When to Recommend Additional Testing
Recommend FDG-PET in ambiguous cases without clear frontotemporal atrophy on MRI 1. However, be aware that non-specific FDG-PET hypometabolism has poor specificity (68%) for distinguishing bvFTD from psychiatric disorders, and such findings should prompt reconsideration of a psychiatric diagnosis 1.
Biomarker Considerations
Strongly recommend CSF or serum neurofilament light chain (NfL) testing when available with age-specific reference values 1. NfL shows excellent diagnostic accuracy (AUC 0.93) for differentiating bvFTD from psychiatric disorders, with sensitivities of 63-100% and specificities of 81-100% 5. This biomarker addresses the major limitation of neuropsychological testing alone.
Genetic Testing Recommendations
Recommend C9orf72 screening in all possible/probable bvFTD cases, even without family history 1. This is particularly important when:
- Prominent psychiatric symptoms are present 1
- Patient doesn't meet full bvFTD criteria but has strong psychiatric features 1
- There is any first-degree relative with FTD, ALS, or late-onset psychiatric disorders 1
C9orf72 mutations can present with heterogeneous neuropsychiatric phenotypes years before typical bvFTD features emerge 1.
Common Diagnostic Pitfalls
Age-Related Considerations
Patients who fail to meet revised diagnostic criteria are typically older and present with atypical features, particularly marked memory impairment that mimics Alzheimer's disease 3. Age also impacts NfL diagnostic accuracy, so age-adjusted reference values are essential 5.
Psychiatric Mimics
Approximately 50% of bvFTD patients receive a prior psychiatric diagnosis (most commonly major depression), with diagnostic delays averaging 5-6 years 1. Conversely, patients with primary psychiatric disorders are frequently misdiagnosed with bvFTD in community settings 1. The symptomatic overlap includes major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders, and personality disorders 1.
Progressive vs. Non-Progressive Presentations
Some patients present with non-progressive bvFTD phenotypes ("phenocopies"), predominantly males with modest cognitive deficits 1. Longitudinal follow-up becomes the diagnostic arbiter in ambiguous cases 1.
Practical Diagnostic Algorithm
Initial screening: Administer general cognitive screening (MoCA, ACE-III) plus at least one social cognition test 1
Comprehensive battery: If bvFTD is in differential, complete assessment of all five cognitive domains plus executive function testing 2
Collateral verification: Obtain detailed informant history documenting behavioral changes and screen for psychiatric symptoms 1
Neuroimaging review: Ensure high-resolution 3D-T1 brain MRI with standardized review protocol has been completed 1
Biomarker consideration: If diagnosis remains uncertain despite clinical evaluation and neuroimaging, recommend NfL testing (serum or CSF) 1, 5
Genetic screening: Recommend C9orf72 testing in all suspected cases, particularly with psychiatric features or relevant family history 1
Longitudinal follow-up: When diagnosis remains ambiguous, serial assessments over time often clarify the diagnosis 1
Your role as a neuropsychologist is to provide detailed cognitive and behavioral characterization that contributes to a multidisciplinary diagnosis, while recognizing that neuropsychological findings alone have insufficient specificity for definitive diagnosis 1.